Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences, Moscow, 109029, Russia; Department of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, 141700, Russia.
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences, Moscow, 109029, Russia; National Medical Research Center of Pediatric Hematology, Oncology and Immunology Named After Dmitry Rogachev, Moscow, 117198, Russia.
Biochem Biophys Res Commun. 2024 Aug 6;720:150099. doi: 10.1016/j.bbrc.2024.150099. Epub 2024 May 10.
Binding of activated factor IX (fIXa) to the phosphatidylserine-expressing procoagulant platelets is a critical step in blood coagulation, which is necessary for the membrane-dependent intrinsic tenase complex assembly and factor X activation. However, the nature and parameters of the fIXa binding sites on the procoagulant platelet surface remain unclear. We used flow cytometry to elucidate the quantitative details of the fluorescently labeled fIXa binding to gel-filtered activated platelets. FIXa bound to the procoagulant platelet subpopulation only, with the parameters (maximal number of binding sites at 58900 ± 3400, K at 1000 ± 170 nM) similar to binding observed with phospholipid vesicles. No specific high-affinity binding sites for fIXa were detected, and binding proceeded similarly for different methods of procoagulant platelet production (thrombin, thrombin receptor activation peptide, collagen-related peptide, their combinations, or calcium ionophore A23187). Factor VIII, known to form a high affinity complex with fIXa, enhanced fIXa binding to platelets. In contrast, only competition effects were observed for factor X, which binds fIXa with much lower affinity. Unexpectedly, fIXa itself, fIX, and prothrombin also dose-dependently enhance fIXa binding at concentrations below 1000 nM, suggesting the formation of membrane-bound fIXa dimers and fIXa-prothrombin complexes on platelets. These findings provide a novel perspective on the fIXa binding site on procoagulant platelets, which does not have any major differences from pure phospholipid-based model membranes, exhibits inherently low affinity (3-5 orders of magnitude below the physiologically relevant fIXa concentration) but is significantly enhanced by its cofactor VIII, and regulated by previously unknown membrane interactions.
激活的因子 IX(fIXa)与表达磷脂酰丝氨酸的促凝血血小板结合是血液凝固的关键步骤,这对于膜依赖的内在凝血酶原复合物组装和因子 X 激活是必要的。然而,促凝血血小板表面上的 fIXa 结合位点的性质和参数仍不清楚。我们使用流式细胞术阐明了荧光标记的 fIXa 与凝胶过滤的激活血小板结合的定量细节。FIXa 仅与促凝血血小板亚群结合,其参数(最大结合位点数为 58900±3400,K 值为 1000±170 nM)与与磷脂囊泡观察到的结合相似。未检测到 fIXa 的特异性高亲和力结合位点,并且不同的促凝血血小板产生方法(凝血酶、凝血酶受体激活肽、胶原相关肽、它们的组合或钙离子载体 A23187)的结合过程相似。已知与 fIXa 形成高亲和力复合物的因子 VIII 增强了 fIXa 与血小板的结合。相比之下,仅观察到因子 X 的竞争效应,因子 X 与 fIXa 的结合亲和力低得多。出乎意料的是,fIXa 本身、fIX 和凝血酶原也在低于 1000 nM 的浓度下剂量依赖性地增强 fIXa 与血小板的结合,这表明在血小板上形成膜结合的 fIXa 二聚体和 fIXa-凝血酶原复合物。这些发现为促凝血血小板上的 fIXa 结合位点提供了新的视角,该结合位点与纯基于磷脂的模型膜没有任何主要区别,表现出固有的低亲和力(比生理相关的 fIXa 浓度低 3-5 个数量级),但被其辅因子 VIII 显著增强,并受以前未知的膜相互作用调节。